Browse Title Index


 
Issue Title
 
Vol 17, No 5 (2021): September/October Role of ultralow dose of naloxone as an adjuvant to fentanyl–bupivacaine in thoracic paravertebral block analgesia after modified radical mastectomy: Randomized controlled trial Abstract
Amany F. Omara, MD, Sameh A. Ahmed, MD, Motaz M. A. Abusabaa, MD
 
Vol 11, No 2 (2015): March/April Root cause analysis of prescription opioid overdoses Abstract
Kelly M. Wawrzyniak, PsyD, Alex Sabo, MD, Ann McDonald, RN, MN, Jeremiah J. Trudeau, PhD, Mon Poulose, MD, Mary Brown, PhD, Nathaniel P. Katz, MD, MS
 
Vol 5, No 4 (2009): July/August Safety and effectiveness of coadministration of intrathecal sufentanil and morphine in hyperbaric bupivacaine-based spinal anesthesia for cesarean section Abstract
Gaetano Draisci, MD, Luciano Frassanito, MD, Raffaella Pinto, MD, Bruno Zanfini, MD, Gabriella Ferrandina, MD, Alessio Valente, MD
 
Vol 6, No 3 (2010): May/June Safety and tolerability of fentanyl iontophoretic transdermal system: Findings from a pooled data analysis of four clinical trials Abstract
Harold S. Minkowitz, MD, Joel Yarmush, MD, Malcolm T. Donnell, MD, Peter H. Tonner, MD, C. V. Damaraju, PhD, Roman J. Skowronski, MD, PhD
 
Vol 2, No 6 (2006): November/December Safety and tolerability of high doses of intrathecal fentanyl for the treatment of chronic pain Abstract   PDF
Sulane Do Ouro, MD, Santiago Esteban, BS, Una Sibirceva, MD, Beverly Whittenberg, MD, Russell Portenoy, MD, Ricardo A. Cruciani, MD, PhD
 
Vol 8, No 5 (2012): September/October Safety and tolerability of OROS® hydromorphone ER in adults with chronic noncancer and cancer pain: Pooled analysis of 13 studies Abstract
Martin E. Hale, MD, Mark S. Wallace, MD, Donald R. Taylor, MD, Michael Kutch, MS, Srinivas Nalamachu, MD
 
Vol 8, No 2 (2012): March/April Safety of EMBEDA® (morphine sulfate and naltrexone hydrochloride) extended-release capsules: Review of postmarketing adverse events during the first year Abstract
Vincent C. Badalamenti, PharmD, Jill W. Buckley, PharmD, Eric T. Smith, PharmD
 
Vol 14, No 2 (2018): March/April Safety profile of intraoperative methadone for analgesia after major spine surgery: An observational study of 1,478 patients Abstract
Lauren K. Dunn, MD, PhD, Sandeep Yerra, MBBS, Shenghao Fang, MSc, Mark F. Hanak, BS, Maren K. Leibowitz, BS, Salome B. Alpert, PhD, Siny Tsang, PhD, Marcel E. Durieux, MD, PhD, Edward C. Nemergut, MD, Bhiken I. Naik, MBBCh
 
Vol 10, No 4 (2014): July/August Save The Date - ICOO 2015 - June 7-9, 2015 Abstract
JOM Editors
 
Vol 2, No 6 (2006): November/December Science at the mercy of the mob: Dr. Hurwitz’s legal problems in perspective Abstract   PDF
Siobhan Reynolds, MA, MFA
 
Vol 11, No 6 (2015): November/December Screening for homelessness among individuals initiating medication-assisted treatment for opioid use disorder in the Veterans Health Administration Abstract
Marcus A. Bachhuber, MD, MSHP, Christopher B. Roberts, MPH, Stephen Metraux, PhD, Ann Elizabeth Montgomery, PhD
 
Vol 7, No 2 (2011): March/April Select practice behaviors of clinicians on the use of opioids for adolescents with subacute and chronic nonmalignant pain Abstract
John M. Saroyan, MD, Wendy Y. Cheng, MPH, Damani C. Taylor, BA, Amna Afzal, MD, Nomita Sonty, MPhil, PhD, Maria A. Sullivan, MD, PhD
 
Vol 11, No 6 (2015): November/December Self-reports of prescription opioid abuse and diversion among recreational opioid users in a Canadian and a United States city Abstract
Beatrice Setnik, PhD, Carl L. Roland, PharmD, MS, Veeraindar Goli, MD, Glenn C. Pixton, MS, Naama Levy-Cooperman, PhD, Ira Smith, MD, Lynn Webster, MD
 
Vol 1, No 4 (2005): September/October September/October 2005 Abstract   PDF
Richard A. DeVito, Jr.
 
Vol 2, No 5 (2006): September/October September/October 2006 Abstract   PDF
Richard A. DeVito, Jr.
 
Vol 3, No 5 (2007): September/October September/October 2007 Abstract
Richard A. DeVito, Jr.
 
Vol 4, No 5 (2008): September/October September/October 2008 Abstract
Richard A. DeVito, Jr.
 
Vol 5, No 5 (2009): September/October September/October 2009 Abstract
Richard A. DeVito, Jr.
 
Vol 6, No 5 (2010): September/October SEPTEMBER/OCTOBER 2010 Abstract
Richard A. DeVito, Jr.
 
Vol 7, No 5 (2011): September/October September/October 2011 Abstract
Richard A. DeVito, Jr.
 
Vol 13, No 5 (2017): September/October September/October 2017, Volume 13, Number 5 Abstract
Richard A. DeVito, Jr.
 
Vol 13, No 2 (2017): March/April Sex differences in the daily rhythmicity of morphine consumption after major abdominal surgery Abstract
Stefano Cattaneo, MD, Pablo Ingelmo, MD, Luigia Scudeller, MD, PhD, Manuela De Gregori, PhD, Dario Bugada, MD, Marco Baciarello, MD, Maurizio Marchesini, MD, Giovanni Alberio, MD, Marco Normanno, MD, Gloria Saccani Jotti, MD, Tiziana Meschi, MD, Guido Fanelli, MD, Massimo Allegri, MD
 
Vol 16, No 5 (2020): September/October Shorter drug testing intervals are associated with improved drug misuse rates Abstract
Jeff Gudin, MD, Neel Mehta, MD, F. Leland McClure, PhD, Justin K. Niles, MA, Harvey W. Kaufman, MD
 
Vol 8, No 1 (2012): January/February Should morphine dosing be weight based for analgesia in the emergency department? Abstract
Asad E. Patanwala, PharmD, Christopher J. Edwards, PharmD, Lori Stolz, MD, Richard Amini, MD, Amol Desai, MD, Uwe Stolz, PhD, MPH
 
Vol 2, No 5 (2006): September/October Significant pain reduction in chronic pain patients after detoxification from high-dose opioids Abstract   PDF
Michael J. Baron, MD, MPH, Paul W. McDonald, PhD
 
Vol 12, No 1 (2016): January/February Simple solution for a complex problem: Rewriting the script Abstract
Xiulu Ruan, MD, Srinivas Chiravuri, MD, Alan David Kaye, MD, PhD
 
Vol 2, No 4 (2006): July/August Single-dose extended-release epidural morphine for pain after hip arthroplasty Abstract   PDF
Gavin Martin, MD, Maximilian Hartmannsgruber, MD, Edward Riley, MD, Garen Manvelian, MD
 
Vol 12, No 2 (2016): March/April Six-month, open-label study of hydrocodone extended release formulated with abuse-deterrence technology: Safety, maintenance of analgesia, and abuse potential Abstract
Martin E. Hale, MD, Yuju Ma, MS, Richard Malamut, MD
 
Vol 3, No 6 (2007): November/December Sleep and daytime sleepiness problems among patients with chronic noncancerous pain receiving long-term opioid therapy: A cross-sectional study Abstract
Aleksandra Zgierska, MD, PhD, Randall T. Brown, MD, Megan Zuelsdorff, BS, David Brown, PhD, Zhengjun Zhang, PhD, Michael F. Fleming, MD, MPH
 
Vol 3, No 3 (2007): May/June Sleep improves when patients with chronic OA pain are managed with morning dosing of once a day extended-release morphine sulfate (AVINZA®): Findings from a pilot study Abstract   PDF
Murray Rosenthal, DO, Polly Moore, PhD, Eric Groves, MD, PhD, Tad Iwan, BA, Lisa Greenberg Schlosser, MS, Zofia Dziewanowska, MD, PhD, Andres Negro-Vilar, MD, PhD
 
Vol 11, No 4 (2015): July/August Sleep-disordered breathing in patients with opioid use disorders in long-term maintenance on buprenorphine-naloxone: A case series Abstract
Jeffrey DeVido, MD, Hilary Connery, MD, PhD, Kevin P. Hill, MD, MHS
 
Vol 14, No 2 (2018): March/April Sourcing of opioid analgesics for nonmedical use: Are veterinarians the latest frontier? Abstract
Cayley Russell, MA, Benedikt Fischer, PhD, Thiago M. Fidalgo, MD, PhD
 
Vol 11, No 1 (2015): January/February Specimen validity testing in urine drug monitoring of medications and illicit drugs: Clinical implications Abstract
Kenneth L. Kirsh, PhD, Paul J. Christo, MD, MBA, Howard Heit, MD, Katherine Steffel, PharmD, Steven D. Passik, PhD
 
Vol 16, No 1 (2020): January/February Staff time requirements for postoperative pain management: Comparison of sufentanil sublingual tablet system and intravenous patient-controlled analgesia Abstract
Thomas Meuser, MD, Stefan Nardi-Hiebl, MSc, MBA, Leopold Eberhart, MD, MA, Matthias Paul, MD, DEAA, Robert Böttger, Jörg Reutershan, MD
 
Vol 13, No 2 (2017): March/April State survey of medical boards regarding abrupt loss of a prescriber of controlled substances Abstract
Leah Sera, PharmD, Micke Brown, BSN, RN, Mary Lynn McPherson, PharmD, Kathryn A. Walker, PharmD, Wendy Klein-Schwartz, PharmD, MPH
 
Vol 12, No 2 (2016): March/April State-level and system-level opioid prescribing policies: The impact on provider practices and overdose deaths, a systematic review Abstract
Francesca L. Beaudoin, MD, MS, Geetanjoli N. Banerjee, MPH, Michael J. Mello, MD, MPH
 
Vol 6, No 5 (2010): September/October Steady-state pharmacokinetics of extended-release hydromorphone (OROS® hydromorphone): A randomized study in healthy volunteers Abstract
Kenneth Todd Moore, MSc, Dominique St-Fleur, BSc, Nadia Cardillo Marricco, MSc, Jay Ariyawansa, MSc, Véronique Pagé, MSc, Jayalakshmi Natarajan, PhD, Gaetano Morelli, MD, FRCP, Ute Richarz, MD
 
Vol 15, No 5 (2019): September/October Storage, security, and disposal Abstract
Robert W. Hutchison, Jr., PharmD, BCACP
 
Vol 4, No 4 (2008): July/August Subcutaneous dexmedetomidine infusions to treat or prevent drug withdrawal in infants and children Abstract
Joseph D. Tobias, MD
 
Vol 8, No 6 (2012): November/December Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: Development and pilot test of a clinical protocol Abstract
Andrew Rosenblum, PhD, Ricardo A. Cruciani, MD, PhD, Eric C. Strain, MD, Charles M. Cleland, PhD, Herman Joseph, PhD, Stephen Magura, PhD, CSW, Lisa A. Marsch, PhD, Laura F. McNicholas, MD, PhD, Seddon R. Savage, MD, MS, Arun Sundaram, BA, Russell K. Portenoy, MD
 
Vol 3, No 5 (2007): September/October Substance dependence and personality disorders: What’s the deal? Details
David Teplin, PsyD, CPsych
 
Vol 14, No 1 (2018): January/February Substance use disorder—substance-induced disorder clinics for pain-medication addictions and addicted patients’ pains: Futuristic need for pain physicians sub-specializing in addiction-medicine Abstract
DeepaK Gupta, MD, Shushovan Chakrabortty, MD, PhD
 
Vol 11, No 6 (2015): November/December Successful interventions in decreasing oxycodone CR prescriptions within an underserved population Abstract
Nipa R. Shah, MD, Judella Haddad-Lacle, MD, Thanh Hogan, Pharm-D
 
Vol 17, No 7 (2021): Special Issue - “Buprenorphine: Clinical and Public Policy Implications" Successful rotation from long-acting full agonist opioids to sublingual buprenorphine/naloxone using a microdosing approach Abstract
René C. Vytialingam, MBBS, FRACGP, FAChAM, Stephan A. Schug, MD, FANZCA, FFPMANZCA, EDPM, Richard O’Regan, MBBS, FAChAM
 
Vol 16, No 2 (2020): March/April Successful use of buprenorphine-naloxone medication-assisted program to treat concurrent pain and opioid addiction after cancer therapy Abstract
Natalie Moryl, MD, Alexandra Filkins, Yvona Griffo, MD, Vivek Malhotra, MD, Raina H. Jain, Ethel Frierson, RN, BSN, OCN, Charles Inturrisi, PhD
 
Vol 9, No 5 (2013): September/October Survey of naloxone legal status in opioid overdose prevention and treatment Abstract
Leanne Hewlett, PharmD, Daniel P. Wermeling, PharmD
 
Vol 13, No 1 (2017): January/February Survey of opioid tapering practices of pediatric healthcare providers: A national perspective Abstract
Deborah Fisher, PhD, RN, PPCNP-BC, Suzanne W. Ameringer, PhD, RN
 
Vol 17, No 2 (2021): March/April Switching a baby from IV levomethadone to IV fentanyl Abstract
Hans Ulrich Bender, MD, Hans-Georg Muench, MD, Claudia Franziska Nussbaum, MD
 
Vol 9, No 4 (2013): July/August Switching from high doses of pure µ-opioid agonists to transdermal buprenorphine in patients with cancer: A feasibility study Abstract
Lena Lundorff, MD, Per Sjøgren, DmSci, MD, Ole Bo Hansen, MD, Torsten Jonsson, MD, Per Rotbøll Nielsen, Lona Christrup, PhD, MSc(Pharm)
 
Vol 16, No 4 (2020): July/August Systematic urine drug testing for detecting and managing opioid misuse among chronic noncancer pain patients in primary care—The HARMS Program: A retrospective chart review of 77 patients Abstract
Niharika Shahi, HBSc, Ryan Patchett-Marble, BSc, MD, CCFP(AM)
 
Vol 3, No 5 (2007): September/October Tactics of the physician-controlled counter—detail and the imminent risk of not changing pharma’s detail relationship with physicians Abstract
Scott A. Kale, MD, JD, MS, Robert L. Barkin, PharmD, MBA
 
Vol 1, No 3 (2005): July/August Taking back your turf: Understanding the role of law in medical decision making in opioid management (Part I—Overview) Abstract   PDF
Jennifer Bolen, JD
 
Vol 1, No 4 (2005): September/October Taking back your turf: Understanding the role of law in medical decision making in opioid management (Part II—Putting legal/regulatory materials to work for you) Abstract   PDF
Jennifer Bolen, JD
 
Vol 17, No 1 (2021): January/February Tales from the frontlines: An alarming rise in hospitalizations related to opioid use disorder in the era of COVID-19 Abstract
Noel Ivey, MD, Dana Cooley Clifton, MD
 
Vol 15, No 1 (2019): January/February Tapentadol immediate release for moderate to severe acute post-surgery pain Abstract
Eugene R. Viscusi, MD, René Allard, PhD, Melanie Sohns, PhD, Mariëlle Eerdekens, MD, MBA
 
Vol 17, No 1 (2021): January/February Tapentadol is the least common opioid found in admission urine drug-test results at an intensive outpatient opioid-use disorder treatment program in Ohio: A brief report Abstract
Adam Rzetelny, PhD, Diana Meske, PhD, Parag Patel, MD, FACOG, FASAM, Steven Passik, PhD
 
Vol 6, No 3 (2010): May/June Tapentadol: An initial analysis Abstract
Eric E. Prommer, MD
 
Vol 7, No 2 (2011): March/April Tapentadol: An initial analysis—follow-up Abstract
Tanya Nelson, PharmD, Vincent Brett, MS, RPh, Eric Prommer, MD
 
Vol 4, No 3 (2008): May/June Tapering chronic opioid therapy in neuropathic facial pain: An interdisciplinary approach Abstract
Brijesh P. Chandwani, BDS, FOP, Ronald J. Kulich, PhD, Lainie Andrew, PhD, Steven Scrivani, DDS, DMedSc
 
Vol 15, No 4 (2019): July/August Tapering off long-term methadone: A case study Abstract
Kehua Zhou, MD, DPT, LAc, Leslie Frankish, BS, Gary G. Wang, MD, PhD
 
Vol 6, No 2 (2010): March/April Teaching clinical opioid pharmacology with the Human Patient Simulator Abstract
Zaki Hassan, MD, Amy DiLorenzo, MA, Paul Sloan, MD
 
Vol 16, No 5 (2020): September/October Tele-fellowships for addiction medicine Abstract
Deepak Gupta, MD
 
Vol 6, No 3 (2010): May/June THE ABUSE OF PRESCRIPTION MEDICATIONS: A RELATIONSHIP WITH BORDERLINE PERSONALITY? Abstract
Randy A. Sansone, MD, Charlene Lam, BS, Michael W. Wiederman, PhD
 
Vol 2, No 3 (2006): May/June The ACTION study: A randomized, open-label, multicenter trial comparing once-a-day extended-release morphine sulfate capsules (AVINZA®) to twice-a-day controlled-release oxycodone hydrochloride tablets (OxyContin®) for the treatment of chronic, moderate to severe low back pain Abstract   PDF
Richard L. Rauck, MD, Stephen A. Bookbinder, MD, Timothy R. Bunker, MD, Christopher D. Alftine, MD, Richard Ghalie, MD, Andres Negro-Vilar, MD, PhD, Egbert de Jong, MD, Steven Gershon, MD
 
Vol 4, No 1 (2008): January/February The addition of haloperidol, propofol, or midazolam to sufentanil for intravenous sedation in the intensive care unit using bispectral index Abstract
Baris Tukenmez, MD, Dilek Memis, MD, Zafer Pamukcu, MD
 
Vol 5, No 1 (2009): January/February The aging methadone maintenance patient: Treatment adjustment, long-term success, and quality of life Abstract
Ranjit Rajaratnam, MD, David Sivesind, PhD, McWelling Todman, PhD, David Roane, MD, Randy Seewald, MD
 
Vol 5, No 6 (2009): November/December The analgesic potential of cannabinoids Abstract
Jaseena Elikottil, MBBS, Pankaj Gupta, MD, Kalpna Gupta, PhD
 
Vol 16, No 5 (2020): September/October The association of opioid use duration and new depression episode among patients with and without insomnia Abstract
Joanne Salas, MPH, Mary Beth Miller, PhD, Jeffrey F. Scherrer, PhD, Rachel Moore, MS, Christina S. McCrae, PhD, Mark D. Sullivan, MD, PhD, Kathleen K. Bucholz, PhD, Laurel A. Copeland, PhD, Brian K. Ahmedani, PhD, F. David Schneider, MD, Patrick J. Lustman, PhD
 
Vol 5, No 6 (2009): November/December The association of opium dependence and postoperative complications following coronary artery bypass graft surgery: A propensity-matched study Abstract
Saeed Sadeghian, MD, Abbasali Karimi, MD, Samaneh Dowlatshahi, MD, Seyed Hossein Ahmadi, MD, Saeed Davoodi, MD, Mehrab Marzban, MD, Namvar Movahedi, MD, Kyomars Abbasi, MD, Mokhtar Tazik, MD, Mahmood Sheikh Fathollahi, PhD
 
Vol 9, No 5 (2013): September/October The characteristics of postoperative fentanyl effect-site concentration during intravenous fentanyl analgesia after posterior lumbar spine fusion Abstract
Tsunehisa Sato, MD, Mutsuhito Kikura, MD, Shigehito Sato, MD, PhD
 
Vol 8, No 5 (2012): September/October The close interaction between medications used for pain management and thyroid function Abstract
Shailendra Kapoor, MD
 
Vol 17, No 7 (2021): Special Issue - “Buprenorphine: Clinical and Public Policy Implications" The divided dose approach to perioperative buprenorphine management in patients with opioid use disorder Abstract
Amanda L. Engle, PharmD, Amanda R.M. Winans, PharmD, Linda Demma, MD, PhD, Jacqueline Cleary, PharmD
 
Vol 17, No 4 (2021): July/August The duration dilemma in opioid agonist therapy Abstract
Anjali Dhanda, MD, Edwin A. Salsitz, MD, DFASAM
 
Vol 6, No 5 (2010): September/October The Eastern North Carolina Opioid Prescribers Project: A model continuing medical education workshop Abstract
Mary K. Crozier, EdD, Sherrá McMillan, PhD Student, Suzanne Hudson, PhD, Stephanie Jones, MS
 
Vol 6, No 1 (2010): January/February The effect of intravenous opioid patient-controlled analgesia with and without background infusion on respiratory depression: A meta-analysis Abstract
Jessica A. George, MD, Elaina E. Lin, MD, Marie N. Hanna, MD, Jamie D. Murphy, MD, Kanupriya Kumar, MD, Phebe S. Ko, BS, Christopher L. Wu, MD
 
Vol 13, No 5 (2017): September/October The effect of toothpicks containing flavoring and flavoring plus jambu extract (spilanthol) to promote salivation in patients diagnosed with opioid-induced dry mouth (xerostomia) Abstract
Bennet Davis, MD, Kathy Davis, ANP-C, Sandy Bigelow, PhD, DABT, Patricia Healey, MPH
 
Vol 1, No 2 (2005): May/June The effect of tramadol or clonidine added to intraperitoneal bupivacaine on postoperative pain in total abdominal hysterectomy Abstract   PDF
Dilek Memis, MD, Alparslan Turan, MD, Beyhan Karamanlioglu, MD, Baris Tükenmez, MD, Zafer Pamukçu, MD
 
Vol 14, No 2 (2018): March/April The effects on patient retention after opioid weaning in an internal medicine residency clinic Abstract
Charles P. Opperman, MD, Melissa M. Butler, MD, Andrew K. Stroud, MD, Michael R. Sun, MD
 
Vol 12, No 2 (2016): March/April The emerging therapeutic roles of κ-opioid agonists Abstract
Mark R. Jones, MD, Alan David Kaye, MD, PhD, Aaron J. Kaye, BA, Richard D. Urman, MD, MBA
 
Vol 7, No 2 (2011): March/April The endocrine effects of long-term oral opioid therapy: A case report and review of the literature Abstract
Jennifer A. Elliott, MD, Erica Horton, DO, Eugene E. Fibuch, MD
 
Vol 11, No 6 (2015): November/December The fear of using tramadol for pain control (tramadolophobia) among Egyptian patients with cancer Abstract
Samy A. Alsirafy, MBBCh, MSc, MD, DipPallMed, Radfan N. Saleh, MBBCh, Radwa Fawzy, MBBCh, Ahmed A. Alnagar, MBBCh, MSc, MD, Ahmed M. Hammad, MBBCh, MSc, Wessam El-Sherief, MBBCh, MSc, MD, Dina E. Farag, MBBCh, MSc, MD, Riham H. Radwan, MBBCh
 
Vol 2, No 5 (2006): September/October The Fourth Circuit Court of Appeals’ decision in United States v. Hurwitz: An important victory for pain management professionals and those living with pain Abstract   PDF
Jennifer Bolen, JD
 
Vol 12, No 6 (2016): November/December The ideal opioid: Is oliceridine the answer? Abstract
Abhijit S. Nair, MD
 
Vol 16, No 3 (2020): May/June The impact of an innovative pharmacist-led inpatient opioid de-escalation intervention in post-operative orthopedic patients Abstract
Thuy Bui, BPharm, Richard Grygiel, MPharm, Alex Konstantatos, MB BS (Hons), FANZCA, Dip Obs, MRCA, Nick Christelis, Susan Liew, MB BS (Hons), FRACS, Ria Hopkins, BHSci (Hons), MPH, Michael Dooley, BPharm, Grad DipHospPharm, PhD
 
Vol 6, No 5 (2010): September/October The impact of financial discharge from methadone maintenance therapy on incarceration Abstract
Nickolas D. Zaller, PhD, Jeannia J. Fu, BSc, Alexander R. Bazazi, BA, Josiah D. Rich, MD, MPH
 
Vol 16, No 6 (2020): November/December The impact of long-term opioid use on the risk and severity of COVID-19 Abstract
Rahul Shah, BS, Yong-Fang Kuo, PhD, Jacques Baillargeon, PhD, Mukaila A. Raji, MD
 
Vol 17, No 2 (2021): March/April The impact of opioid prescribing reduction interventions on prescribing patterns across orthopedic subspecialties Abstract
Justin Turcotte, PhD, MBA, Kevin Crowley, MBA, MS, PT, Stephanie Adams, MEd, David Keblish, MD, Cyrus Lashgari, MD, Chad Patton, MD, MS, Benjamin Petre, MD, Paul King, MD, Jeffrey Gelfand, MD
 
Vol 14, No 4 (2018): July/August The impact of preinduction fentanyl dosing strategy on postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy Abstract
Amitabh Dutta, MD, Nitin Sethi, DNB, Prabhat Choudhary, MD, Jayashree Sood, MD, Bhuwan Chand Panday, MD, Parul Takkar Chugh, MSc
 
Vol 2, No 4 (2006): July/August The influence of chief complaint on opioid use in the emergency department Abstract   PDF
Kathleen Puntillo, RN, DNSc, FAAN, Martha Neighbor, MD, Garrett K. Chan, APRN, BC, PhD, Roxanne Garbez, RN, MS, ACNP
 
Vol 1, No 3 (2005): July/August The metamorphosis of hydromorphone Abstract   PDF
Gary M. Reisfield, MD, George R. Wilson, MD
 
Vol 9, No 4 (2013): July/August The misuse of prescription pain medication and borderline personality symptomatology Abstract
Randy A. Sansone, MD, Daron A. Watts, MD, Michael W. Wiederman, PhD
 
Vol 14, No 6 (2018): November/December The natural history of prescription opioid abuse: A pilot study exploring change in routes of administration and motivation for changes Abstract
Stacey McCaffrey, PhD, Kelly A. Manser, BA, Kimberlee J. Trudeau, PhD, Gwendolyn Niebler, DO, Colville Brown, MD, Donna Zarycranski, MS, Simon H Budman, PhD
 
Vol 1, No 3 (2005): July/August The opioid bowel syndrome: A review of pathophysiology and treatment Abstract   PDF
Mellar P. Davis, MD, FCCP
 
Vol 8, No 1 (2012): January/February The Opioid Manager: A point-of-care tool to facilitate the use of the Canadian Opioid Guideline Abstract
Andrea D. Furlan, MD, PhD, Rhoda Reardon, Dip(P&OT), Lena Salach, MA
 
Vol 5, No 1 (2009): January/February The opioid-exposed newborn: Assessment and pharmacologic management Abstract
Lauren M. Jansson, MD, Martha Velez, MD, Cheryl Harrow, RNC-LRN, MS, FNP-BC, IBCLC, RLC
 
Vol 14, No 2 (2018): March/April The parenteral opioid shortage: Causes and solutions Abstract
Hanna Hollingsworth, PharmD, Chris Herndon, PharmD, CPE
 
Vol 11, No 2 (2015): March/April The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment Abstract
Bimal K. Malhotra, PhD, Grant L. Schoenhard, PhD, Annelies W. de Kater, PhD, Nadav Friedmann, PhD, MD
 
Vol 12, No 2 (2016): March/April The prescription opioid epidemic in developed versus underdeveloped countries: Is there a happy medium? Abstract
Roland N. Kaddoum, MD, Doralina L. Anghelescu, MD, Cynthia Karam, Marie T. Aouad, MD, Eveline Hitti, MD, MBA
 
Vol 9, No 4 (2013): July/August The prevalence and economic impact of prescription opioid-related side effects among patients with chronic noncancer pain Abstract
Jasmina I. Ivanova, MA, Howard G. Birnbaum, PhD, Yana Yushkina, BA, Rachael A. Sorg, MPH, John Reed, MD, Sanjay Merchant, MBA, PhD
 
Vol 13, No 2 (2017): March/April The prevalence of nasal obstruction as a consideration in the treatment of opioid overdose Abstract
Scott G. Weiner, MD, MPH, Andrew R. Joyce, PhD, Heather N. Thomson, MS
 
Vol 6, No 6 (2010): November/December The relationship between opioid and sugar intake: Review of evidence and clinical applications Abstract
David J. Mysels, MD, MBA, Maria A. Sullivan, MD, PhD
 
Vol 14, No 6 (2018): November/December The role of multimodal analgesia in preventing the development of chronic postsurgical pain and reducing postoperative opioid use Abstract
Wenling Jian, MD, Damoon Rejaei, MD, Ahmed Shihab, MD, Theodore A. Alston, MD, PhD, Jingping Wang, MD, PhD
 
Vol 14, No 1 (2018): January/February The role of transdermal compounding in opioid safety Abstract
Caitlin V. Bucher, PharmD, A.J. Day, PharmD, Maria Carvalho, PhD
 
Vol 3, No 5 (2007): September/October The safety and tolerability of the fentanyl HCl iontophoretic transdermal system: An alternative to currently available analgesic modalities Abstract
Leopold Eberhart, MD
 
Vol 2, No 2 (2006): March/April The US Supreme Court decision on assisted suicide and the prescription of pain medication: Limit the celebration Abstract   PDF
Marshall B. Kapp, JD, MPH
 
Vol 5, No 1 (2009): January/February The use of methadone “as needed”, is it justified? Details
John F. Peppin, DO, FACP
 
Vol 5, No 6 (2009): November/December The use of opioids in a pregnant woman with lumbar disc herniation: A case report Abstract
Emi Matsumoto, MD, Kazuaki Yoshimura, MD, Eiichiro Nakamura, MD, Toru Hachisuga, MD, Masamichi Kashimura, MD
 
Vol 9, No 2 (2013): March/April The use of urine drug monitoring in chronic opioid therapy: An analysis of current clinician behavior Abstract
Zoe Clancy, PharmD, Katherine O’Connell, BS, Joseph Couto, PharmD, MBA
 
Vol 1, No 4 (2005): September/October The World Institute of Pain: Advancing research and clinical practice Abstract   PDF
Stephen J. Ziegler, PhD, JD
 
Vol 6, No 3 (2010): May/June THORACIC EPIDURAL ANALGESICS PROVIDE EXCELLENT CANCER PAIN RELIEF AT THE END OF LIFE Abstract
Paul A. Sloan, MD
 
Vol 9, No 4 (2013): July/August Time to include buprenorphine-naloxone combination in the WHO model list of essential medicines Abstract
Yatan Pal Singh Balhara, MBBS, MD, DNB, MNAMS
 
Vol 11, No 5 (2015): September/October Tolerability and efficacy of tapentadol extended release in elderly patients ≥75 years of age with chronic osteoarthritis knee or low back pain Abstract
David M. Biondi, DO, Jim Xiang, PhD, Mila Etropolski, MD, Bruce Moskovitz, MD
 
Vol 8, No 2 (2012): March/April Tolerability and efficacy of two synergistic ratios of oral morphine and oxycodone combinations versus morphine in patients with chronic noncancer pain Abstract
Felix A. de la Iglesia, MD, Gary W. Pace, PhD, Gary L. W. G. Robinson, PhD, Nuo-Yu Huang, MD, PhD, Warren Stern, PhD, Patricia Richards, MD, PhD
 
Vol 7, No 2 (2011): March/April Torsades-de-Pointes associated with Taku-Tsubo cardiomyopathy following greatly reduced oxycodone use in an elderly woman Abstract
Harry W. Daniell, MD
 
Vol 13, No 5 (2017): September/October Tramadol for maintenance in opioid dependence: A retrospective chart revie Abstract
Siddharth Sarkar, MD, DNB, Rakesh Lal, MD, Mohit Varshney, MD, Yatan Pal Singh Balhara, MD, DNB, MNAMS
 
Vol 11, No 4 (2015): July/August Tramadol versus codeine/acetaminophen after pediatric tonsillectomy: A prospective, double-blinded, randomized controlled trial Abstract
Stefan J. Friedrichsdorf, MD, FAAP, Andrea C. Postier, MPH, Laurie Pane Foster, MEd, Timothy A. Lander, MD, Robert J. Tibesar, MD, Yi Lu, MS, James D. Sidman, MD
 
Vol 1, No 3 (2005): July/August Tramadol: Does it have a role in cancer pain management? Abstract   PDF
Eric E. Prommer, MD
 
Vol 13, No 3 (2017): May/June Tramadol-associated mania: A case report Abstract
Jamaluddin Nimah, MD, Alexander Chen, BA, Kelly N. Gable, PharmD, BCPP, Alan R. Felthous, MD
 
Vol 16, No 4 (2020): July/August Transdermal Fentanyl patch: An approach to enhance tolerance of conscious proning in COVID-19 patients Abstract
Sowmia Mammen, MBBS, DNB, Beena Yousuf, MBBS, FCPS, Mohammad Shamsah, MBBS, FRCPC
 
Vol 10, No 2 (2014): March/April Transdermal opioids for cancer pain control in patients with renal impairment Abstract
Giuseppe Melilli, MD, Boaz Gedaliahu Samolsky Dekel, MD, PhD, MA, Catia Frenquelli, MD, Rita Mellone, MD, Franco Pannuti, MD
 
Vol 12, No 5 (2016): September/October Transient low testosterone levels after oral hydrocodone may contribute to misdiagnosis of hypogonadism Abstract
Harry W. Daniell, MD
 
Vol 13, No 3 (2017): May/June Treating postoperative pain in the patient who is in recovery or remission from opioid abuse: Focus on Tapentadol Abstract
Robert L. Barkin, MBA, PharmD, FCP, DAAPM, DACFE, DACPS, Stacy J. Barkin, BA, MA, MEd, PsyD
 
Vol 11, No 1 (2015): January/February Treatment changes following aberrant urine drug test results for patients prescribed chronic opioid therapy Abstract
Benjamin J. Morasco, PhD, Erin E. Krebs, MD, MPH, Renee Cavanagh, MS, Stephanie Hyde, MA, Aysha Crain, MSW, Steven K. Dobscha, MD
 
Vol 16, No 5 (2020): September/October Treatment for kratom abuse in a contingency-management-based MAT setting: A case series Abstract
Seth Kalin, MD, Salaahuddin Dakhlalla, MD, Saurabh Bhardwaj, MD
 
Vol 10, No 1 (2014): January/February Treatment of opioid-related central sleep apnea with positive airway pressure: A systematic review Abstract
Roopika Reddy, MD, David Adamo, RPSGT, Thomas Kufel, MD, Jahan Porhomayon, MD, Ali A. El-Solh, MD, MPH
 
Vol 14, No 4 (2018): July/August Trends in and predictors of hydromorphone administration in US emergency departments (2007-2014) Abstract
Maryann Mazer-Amirshahi, PharmD, MD, MPH, Diana Ladkany, MD, Peter M. Mullins, MA, MPH, Sergey Motov, MD, Jeanmarie Perrone, MD, Lewis S. Nelson, MD, Jesse M. Pines, MD, MBA, MSCE
 
Vol 11, No 1 (2015): January/February Trends in drug use from urine drug testing of addiction treatment clients Abstract
Kenneth L. Kirsh, PhD, Howard A. Heit, MD, Angela Huskey, PharmD, CPE, Jennifer Strickland, PharmD, BCPS, Kathleen Egan City, MA, BSN, RN, Steven D. Passik, PhD
 
Vol 13, No 5 (2017): September/October Trends in Florida's Prescription Drug Monitoring Program registration and utilization: Implications for increasing voluntary use Abstract
Chris Delcher, PhD, Yanning Wang, MS, Henry W. Young, MD, Bruce A. Goldberger, PhD, Siegfried Schmidt, MD, PhD, FAAFP, Gary M. Reisfield, MD
 
Vol 3, No 4 (2007): July/August Trends in nonheroin opioid abuse admissions: 1992-2004 Abstract
Kathleen S. Peindl, PhD, Paolo Mannelli, MD, Li-Tzy Wu, ScD, Ashwin A. Patkar, MD
 
Vol 11, No 4 (2015): July/August Triple dosing with high doses of buprenorphine: Withdrawal Abstract
Erland Hvittfeldt, MD, Charlotte Gedeon, MD, Ingrid Fridolf, MLS, Anders Håkansson, MD, PhD
 
Vol 11, No 5 (2015): September/October Twelve-month, open-label assessment of long-term safety and abuse potential of hydrocodone extended-release formulated with abuse-deterrence technology in patients with chronic pain Abstract
Martin E. Hale, MD, Thomas R. Zimmerman, Jr, MD, Yuju Ma, MS, Richard Malamut, MD
 
Vol 5, No 2 (2009): March/April Two milligrams IV hydromorphone is efficacious for treating pain but is associated with oxygen desaturation Abstract
Andrew K. Chang, MD, MS, Polly E. Bijur, PhD, Antonio Napolitano, MD, Jason Lupow, MD, E. John Gallagher, MD
 
Vol 9, No 2 (2013): March/April Ultralow dose fentanyl prevents development of chronic neuropathic pain in rats Abstract
Elzbieta P. Wala, PhD, Joseph R. Holtman Jr, MD, PhD, Paul A. Sloan, MD
 
Vol 2, No 5 (2006): September/October Ultra-low-dose opioid antagonists to enhance opioid analgesia Abstract   PDF
Paul Sloan, MD, Scott Hamann, PhD, MD
 
Vol 7, No 5 (2011): September/October Ultra-rapid opiate detoxification using dexmedetomidine under general anesthesia Abstract
Dalia Abdelhamid Mohamed Nasr, MD, Hani Abdelfattah Said Ahmed Omran, MD, Sameh Michel Hakim, MD, Waleed Ahmed Abdelrahman Mansour, MD
 
Vol 15, No 2 (2019): March/April Understanding transdermal buprenorphine and a practical guide to its use for chronic cancer and non-cancer pain management Abstract
Tony O’Brien, MB, FRCPI, Jin Seok Ahn, MD, Richard Chye, MBBS, FRACP, FFPMANZCA, FAChPM, Brian Le, MBBS (Hons), MPH, FRACP, FAChPM, Henry Lu, MD, DABPN, DPBPM, Gabriel Olarte, MD, Mariana Palladini, MD, Amar Salti, MD, EDRA, Yu-Yun Shao, MD, PhD, Hayati Yaakup, MBBS, MMED (UKM), PgDip, Kristal Cielo Buemio, MD, Consuelo Gutierrez Colin, MD, Yacine Hadjiat, MD
 
Vol 9, No 3 (2013): May/June Undetected Ultracet™ dependence in an adolescent with nonmalignant back pain Abstract
Nabil A. Khan, BA, Maria A. Sullivan, MD, PhD, Michael G. Vitale, MD, MPH, Mary Ellen Tresgallo, DNP, MPH, MS, John M. Saroyan, MD
 
Vol 8, No 1 (2012): January/February Urinalysis-based comparative evaluation of pattern of use of dextropropoxyphene and buprenorphine among opioid-dependent subjects Abstract
Yatan Pal Singh Balhara, MD, DNB (Psychiatry), MNAMS, Raka Jain, PhD, CChem, FRSC
 
Vol 3, No 2 (2007): March/April Urine drug test interpretation: What do physicians know? Abstract   PDF
Gary M. Reisfield, MD, Roger Bertholf PhD, Robert L. Barkin, MBA, PharmD, Fern Webb, PhD, George Wilson, MD
 
Vol 3, No 6 (2007): November/December Use and misuse of buprenorphine in the management of opioid addiction Abstract
Theodore J. Cicero, PhD, Hilary L. Surratt, PhD, James Inciardi, PhD
 
Vol 1, No 2 (2005): May/June Use of a comprehensive survey as a first step in addressing clinical competence of physicians-in-training in the management of pain Abstract   PDF
Mark Chaitowitz, MBBCh, William Tester, MD, Glenn Eiger, MD
 
Vol 5, No 6 (2009): November/December Use of an algorithm applied to urine drug screening to assess adherence to an OxyContin® regimen Abstract
Joseph E. Couto, PharmD, MBA, Lynn Webster, MD, FACPM, FASAM, Martha C. Romney, MS, JD, MPH, Harry L. Leider, MD, MBA, Ariel Linden, DrPH, MS
 
Vol 6, No 1 (2010): January/February Use of sublingual methadone for treating pain of chemotherapy-induced oral mucositis Abstract
Anita Gupta, DO, PharmD, Benjamin Duckles, MD, James Giordano, MPhil, PhD
 
Vol 9, No 1 (2013): January/February Use of tincture of opium compared to oral morphine for the treatment of neonatal abstinence syndrome Abstract
Suzannah Kokotajlo, PharmD, Christine A. Robinson, PharmD, Amy Presti, MD, MSCR
 
Vol 9, No 3 (2013): May/June Usefulness of the opioid risk tool to predict aberrant drug-related behavior in patients receiving opioids for the treatment of chronic pain Abstract
Lisa R. Witkin, MD, Dina Diskina, BS, Shawn Fernandes, BS, John T. Farrar, MD, PhD, Michael A. Ashburn, MD, MPH
 
Vol 3, No 2 (2007): March/April Using methadone to treat opioid-induced hyperalgesia and refractory pain Abstract   PDF
David J. Axelrod, MD, JD, Barbara Reville, MS, CRNP
 
Vol 11, No 1 (2015): January/February Using urine drug testing to support healthy boundaries in clinical care Abstract
Howard A. Heit, MD, FACP, FASAM, Douglas L. Gourlay, MD, MSc, FRCPC, FASAM
 
Vol 6, No 2 (2010): March/April Utility of transdermal fentanyl for prevention of iatrogenic opioid abstinence syndrome in children Abstract
Peter N. Johnson, PharmD, BCPS, Donald Harrison, PhD, Christine Allen, MD
 
Vol 11, No 2 (2015): March/April Validation of a new risk assessment tool: The Brief Risk Questionnaire Abstract
Ted Jones, PhD, Samantha Lookatch, MA, Todd Moore, PhD
 
Vol 15, No 6 (2019): November/December Validation of the prescription drug monitoring program Web site Abstract
Bryan A. Hozack, MD, Michael Rivlin, MD, Jack Graham, BS, Kevin F. Lutsky, MD, Pedro K. Beredjiklian, MD
 
Vol 15, No 4 (2019): July/August Validity of the screener and opioid assessment for patients with pain-revised (SOAPP-R) in patients with cancer Abstract
Junaid T. Yasin, MPH, Amy E. Leader, DrPH, MPH, Alison Petok, MSW, MPH, Gregory Garber, MSW, Britainy Stephens, MSW, Brooke Worster, MD
 
Vol 6, No 1 (2010): January/February Variability of transdermal fentanyl metabolism and excretion in pain patients Abstract
Joanna M. Cole, BA, Brookie M. Best, PharmD, MAS, Amadeo J. Pesce, PhD, DABCC
 
Vol 4, No 1 (2008): January/February Very-low-dose ketamine for the management of pain and sedation in the ICU Abstract
Mario De Pinto, MD, Jill Jelacic, MD, William T. Edwards, PhD, MD
 
Vol 10, No 1 (2014): January/February Volume 10, Number 1, January/February 2014 Abstract
Richard A. DeVito, Jr.
 
Vol 10, No 2 (2014): March/April Volume 10, Number 2, March/April 2014 Abstract
Richard A. DeVito, Jr.
 
Vol 12, No 5 (2016): September/October Volume 12, Number 5; Journal of Opioid Management; September/October 2016 Abstract
Weston Medical Publishing, LLC
 
Vol 13, No 2 (2017): March/April Volume 13, Number 2 Abstract
Richard A. DeVito, Jr.
 
Vol 13, No 3 (2017): May/June Volume 13, Number 3, May/June 2017 Abstract
Richard A DeVito, Jr.
 
Vol 13, No 4 (2017): July/August Volume 13, Number 4 Abstract
Richard A. DeVito, Jr.
 
Vol 14, No 1 (2018): January/February Volume 14, Number 1 Abstract
Richard A. DeVito, Jr.
 
Vol 14, No 2 (2018): March/April Volume 14, Number 2 Abstract
Richard A. DeVito, Jr.
 
Vol 14, No 3 (2018): May/June Volume 14, Number 3 May/June 2018 Abstract
Richard A. DeVito, Jr.
 
Vol 14, No 4 (2018): July/August Volume 14, Number 4 Abstract
Richard A. DeVito, Jr.
 
Vol 14, No 5 (2018): September/October Volume 14, Number 5 Abstract
Richard A. DeVito, Jr.
 
Vol 14, No 6 (2018): November/December Volume 14, Number 6 Abstract
Richard A. DeVito, Jr.
 
Vol 15, No 1 (2019): January/February Volume 15, Number 1 Abstract
Journal of Opioid Management
 
Vol 15, No 2 (2019): March/April Volume 15, Number 2 Abstract
Journal of Opioid Management
 
Vol 15, No 4 (2019): July/August Volume 15, Number 4 Abstract
Journal of Opioid Management
 
Vol 15, No 5 (2019): September/October Volume 15, Number 5 Abstract
Journal of Opioid Management
 
Vol 15, No 6 (2019): November/December Volume 15, Number 6 Abstract
Journal of Opioid Management
 
Vol 16, No 1 (2020): January/February Volume 16, Number 1 Abstract
Journal of Opioid Management
 
Vol 16, No 2 (2020): March/April Volume 16, Number 2 Abstract
Journal of Opioid Management
 
Vol 16, No 3 (2020): May/June Volume 16, Number 3 Abstract
Journal of Opioid Management
 
Vol 16, No 4 (2020): July/August Volume 16, Number 4 Abstract
Journal of Opioid Management
 
Vol 16, No 5 (2020): September/October Volume 16, Number 5 Abstract
Journal of Opioid Management
 
Vol 16, No 6 (2020): November/December Volume 16, Number 6 Abstract
Journal of Opioid Management
 
Vol 17, No 1 (2021): January/February Volume 17, Number 1 Abstract
Journal of Opioid Management
 
Vol 17, No 2 (2021): March/April Volume 17, Number 2 Abstract
Journal of Opioid Management
 
Vol 17, No 3 (2021): May/June Volume 17, Number 3 Abstract
Journal of Opioid Management
 
Vol 17, No 4 (2021): July/August Volume 17, Number 4 Abstract
Journal of Opioid Management
 
Vol 17, No 5 (2021): September/October Volume 17, Number 5 Abstract
Journal of Opioid Management
 
Vol 8, No 3 (2012): May/June Volume 8, Number 3 Abstract
Richard A. DeVito, Jr.
 
Vol 8, No 4 (2012): July/August Volume 8, Number 4 Abstract
Richard A. DeVito, Jr.
 
Vol 8, No 5 (2012): September/October Volume 8, Number 5 Abstract
Richard A. DeVito, Jr.
 
Vol 9, No 5 (2013): September/October Volume 9, Number 5; September/October 2013 Abstract
Richard A. DeVito, Jr.
 
Vol 9, No 6 (2013): November/December Volume 9, Number 6, November/December 2013 Abstract
Richard A. DeVito, Jr
 
Vol 6, No 1 (2010): January/February Weaning of opioids and benzodiazepines at home after critical illness in infants: A cost-effective approach Abstract
Erwin Ista, PhD, RN, Monique van Dijk, PhD, Saskia Gischler, MD, PhD, Mirjam de Leeuw, RN, Marten J. Poley, PhD, Dick Tibboel, MD, PhD
 
Vol 1, No 5 (2005): November/December What can we learn from baseball’s steroid scandal? Abstract   PDF
Gary M. Reisfield, MD, George R. Wilson, MD
 
Vol 10, No 2 (2014): March/April What do we need to be telling our patients about opioids together with acetaminophen? Details
Robert Hutchison, PharmD, BCACP
 
Vol 15, No 2 (2019): March/April What happens if the neighbor’s medication is used? Accidental intoxication due to fentanyl transdermal patch Abstract
Hande Gurbuz Aytuluk, MD
 
Vol 15, No 6 (2019): November/December What physicians need to implement safer opioid prescribing: A qualitative study Abstract
Allison Navis, MD, Mary Catherine George, PhD, Maya Scherer, MPH, Linda Weiss, PhD, Yosuke Chikamoto, PhD, Jessica Robinson-Papp, MS, MD
 
Vol 12, No 4 (2016): July/August What's in a number? Recommending practicality in the DATA 2000 patient limits Abstract
Andrea G. Barthwell, MD, DFASAM, Jonathan M. Young, JD, PhD, Michael C. Barnes, JD, Shruti R. Kulkarni, JD
 
Vol 8, No 5 (2012): September/October Which skills are associated with residents’ sense of preparedness to manage chronic pain? Abstract
Aaron D. Fox, MD, MS, Hillary V. Kunins, MD, MPH, MS, Joanna L. Starrels, MD, MS
 
Vol 1, No 1 (2005): March/April Who should regulate the practice of medicine? Abstract   PDF
Erin A. Egan, MD, JD
 
Vol 8, No 6 (2012): November/December Why do emergency providers choose one opioid over another? A prospective cohort analysis Abstract
Alec B. O’Connor, MD, MPH
 
Vol 4, No 1 (2008): January/February Why does the pain specialist not meet the needs of the referring physicians? Details
Asokumar Buvanendran, MD
 
Vol 17, No 2 (2021): March/April Why we still prescribe so many opioids: A qualitative study on barriers and facilitators to prescribing guideline implementation Abstract
Kathryn W. Zavaleta, MHSA, Lindsey M. Philpot, PhD, MPH, Julie L. Cunningham, PharmD, RPh, Halena M. Gazelka, MD, Holly L. Geyer, MD, Denise L. Rismeyer, MSN, RN, NPD-BC, Amber M. Stitz, DNP, APRN, ACNS-BC, Casey M. Clements, MD, PhD
 
Vol 1, No 1 (2005): March/April With the withdrawal of COX-2 inhibitors, opioids are an obvious alternative choice for pain Abstract   PDF
Rob Hutchison, PharmD
 
Vol 7, No 1 (2011): January/February Ziconotide: A rapid detoxification protocol for the conversion from intrathecal morphine–The Raffaeli Detoxification Model Abstract
William Raffaeli, MD, Donatella Righetti, MD, Donatella Sarti, PhD, Marco Balestri, MD, Isabella Ferioli, MD, Maria Cristina Monterubbianesi, MD, Alessandro Caminiti, MD
 
Vol 17, No 2 (2021): March/April Zinc deficiency: A cause of opioid-induced physical dependence and addiction in post-operative total hip arthroplasty patients Abstract
Tyler J. Tantillo, DO, Manoj R. Jagtiani, DO, Eric R. Silverman, MD, Adam D. Bitterman, DO, Giles R. Scuderi, MD
 
751 - 950 of 950 Items << < 1 2 3 4